Benzo[A] [phenazin-11-carboxamide derivatives and their use as joint inhibitors of topomerase I and II

Number of patents in Portfolio can not be more than 2000

United States of America Patent

APP PUB NO 20030139409A1
SERIAL NO

10148601

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

A compound which is a benzo[a]phenazine-11-carboxamide derivative of formula (I) wherein each of R.sup.1 to R.sup.4, which are the same or different, is selected from hydrogen, halogen, hydroxyl, C.sub.1-C.sub.6 alkoxy which is unsubstituted or substituted, heteroaryloxy, C.sub.1-C.sub.6 alkyl which is unsubstituted or substituted, nitro, cyano, azido, amidoxime, CO.sub.2R.sup.10, CON(R.sup.12).sub.2, OCON(R.sup.12), SR.sup.10, SOR.sup.11, SO.sub.2(R.sup.11), SO.sub.2N(R.sup.12).sub.2, N(R.sup.12).sub.2, NR.sup.10SO.sub.2R.sup.11, N(SO.sub.2R.sup.11).sub.2NR.sup.10(CH.sub.2).sub.nCN, NR.sup.10COR.sup.11, OCOR.sup.11 or COR.sup.10; each of R.sup.5 to R.sup.7, which are the same or different, is selected from hydrogen, halogen, hydroxy, C.sub.1-C.sub.6 alkoxy, C.sub.1-C.sub.6 alkyl, SR.sup.10 and N(R.sup.12).sub.2; Q is C.sub.1-C.sub.6 alkylene which is unsubstituted or substituted by (i) C.sub.1-C.sub.6 alkyl which is unsubstituted or substituted, (ii) hydroxy, provided that the hydroxy group is not, to either of the N atoms adjacent to Q in formula (I), (iii) CO.sub.2R.sup.10, or (iv) CON(R.sup.12); R.sup.1 and R.sup.9, which are the same or different, are each hydrogen or C.sub.1-C.sub.6 alkyl, or R.sup.8 and R.sup.9 together with the nitrogen atom to which they are attached form a saturated 5- or 6-membered N-containing heterocyclic ring which may include one additional heteroatom selected from O, N and S, or one of R.sup.8 and R.sup.9 is an alkylene chain optionally interrupted by O, N or S, which is attached to a carbon atom on the alkylene chain represented by Q to complete a saturated 5- or 6-membered N-containing heterocyclic ring as defined above; or a pharmaceutically acceptable salt thereof; with the proviso that at least one R.sup.1 to R.sup.4 is other than hydrogen. These compounds are inhibitors of topoisomerase I and/or topoisomerase II and can be used to treat tumours, including tumours which express MDR.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
XENOVA LIMITEDSLOUGH

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Denny, William Alexander Auckland, NZ 66 1257
Folkes, Adrian Berkshire, GB 34 911
Milton, John Berkshire, GB 71 3846
Vicker, Nigel Berkshire, GB 22 104
Wang, Shouming Berkshire, GB 11 21

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation